Literature DB >> 22875125

[Juvenile myoclonic epilepsy].

Marte Roa Syvertsen1, Rune Markhus, Kaja Kristine Selmer, Karl O Nakken.   

Abstract

BACKGROUND: Juvenile myoclonic epilepsy (JME) is a generalised epilepsy with seizure onset in youth. The aim of this review is to present updated knowledge about the etiology, diagnosis and treatment of JME. MATERIAL AND
METHOD: The review is based on a judicious selection of original English language articles, meta-analyses, and reviews found in PubMed, and the authors' own experience with the patient group.
RESULTS: Seizure onset occurs in adolescence. All have myoclonias, about 90 % have generalized tonic-clonic seizures, and one third have absences. Myoclonic jerks are frequently the debut symptom, while tonic-clonic seizures appear later on. Patients are particularly susceptible to seizures shortly after waking. It is important to ask specifically about myoclonias as most patients do not report jerks spontaneously. The electroencephalograms of 44-81 % of the patients show discharges of 4-6 Hz polyspike waves. Focal EEG abnormalities may be seen in about 30 %. When patients are treated with valproate and seizure-precipitating factors are avoided, especially sleep deprivation, about 80 % become seizure-free. Lamotrigine and levetiracetam are alternative therapies for women of childbearing age. Attempts to taper off the medication after several years of seizure freedom entail a high risk of seizure relapse.
INTERPRETATION: As there may be features of focal epilepsy in the seizure semiology and/or the EEGs, it may be difficult to diagnose JME. Thus, many patients are misdiagnosed as having a focal epilepsy and are given antiepileptic drugs that may aggravate the tendency to seizures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875125     DOI: 10.4045/tidsskr.11.1518

Source DB:  PubMed          Journal:  Tidsskr Nor Laegeforen        ISSN: 0029-2001


  1 in total

1.  Clinical Evaluation of 38 Patients with Juvenile Myoclonic Epilepsy.

Authors:  Abdorreza Naser Moghadasi; Mahmood Motamedi; Razieh Aghakhani; Mahsa Owji
Journal:  Iran J Public Health       Date:  2014-05       Impact factor: 1.429

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.